Blood resin abnormalities are one of the major risk factors for the sclerosis of the aortic porridge and coronary porridges. Studies have shown that haemoglobin abnormalities and smoking are two of the strongest risk factors, which together explain two thirds of the risk of heart attack. As the standard of living improves and ageing, the rate of haemoglobin abnormality among the Chinese population continues to rise, and even many patients are accompanied by acoustic porridge stubble. As a result, the management of blood resin in the public is imminent. It is particularly important to conduct blood resin management at the grass-roots level. Thus, the Chinese blood resin management guide (2024 basic edition) was issued this year to guide the management of high-lipid haemorrhagic disease in primary hospitals.
Low-density lipoprotein C (LDL-C) is the primary target for blood resin interventions. The impact of LDL-C levels on patients is not overnight, and is not limited to a certain lipid level or at a certain point in time. Rather, over time, there has been an ongoing cumulative effect on the progress of non-symptomatic spots and the occurrence of cardiovascular events. The effects of LDL-C cumulative exposure are confirmed by recent studies. Regardless of the LDL-C level and age of the patient, the LDL-C cumulative exposure is associated with the absolute risk of aerostatic cardiovascular events in the avionic porridge sample. The lower the LDL-C, the more we can significantly delay the time we get coronary heart disease. The goal of lipid reduction treatment should be not only short-term blood resin control but also long-term adherence. The target was not a one-size-fits-all, but a different target value based on the hazard layer of coronary porridge sclerosis. First, there is a second and first level of prevention, depending on whether the patient suffers from a coronary porridge. The hazard layer is also based on the number of high-risk factors (e.g. hypertension, diabetes, chronic kidney disease, obesity, smoking, etc.) (please ask your doctor for more details). For low-risk, medium/high-risk, high-risk and ultra-high-risk patients, the target targets for low-density lipoprotein C are 3.4, 2.6, 1.8 (and more than 50 per cent lower than baseline) and 1.4mol/L (and more than 50 per cent lower than baseline).
The treatment of high cholesterol sepsis can be treated with medium-intensity meds as an initial drug. The use of high-intensity carcasses can have side effects such as absic pain, hepatic enzymes, haematosis, and new diabetes, especially when combined with pressure-relief drugs such as calcium-traffic retardants, the symptoms of the side effects and regular blood checks are observed. The dosage of the drug has doubled, with a 6 per cent increase in lipid reduction. So if cholesterol and low-density lipid protein C do not meet the standard, cholesterol absorbs inhibitors, PCSK9 inhibitors, Probco and other lipids.
The PCSK9 inhibitors currently on the market are Iloyo, Alisiu, Toletsi and RNA Incksland. In addition to LDL-C compliance, the stabilization of plasters and even their reduction are essential for the prevention of coronary heart disease and cardiovascular events. He can stabilize and, to a certain extent, reduce the specks, with his edibles and Probco. The new type of lipid-reducing drug, the PCSK9 inhibitor, has a more stable and less tectonic effect because of its more visible effects.
Iloyu, against 140 mg or Alisiu, against 75 mg and one per fortnightly subcutaneous, safe and tolerant, will significantly reduce the LDL-C level by ~70%. The incidence of adverse reactions, such as severe adverse events, muscular-related events, new diabetes, hemorrhagic cerebral and neurocognostic events, is similar to that of the placebo group. A similar reduction in low-density protein C can also be obtained from a perforated injection of 150 mg per week or per month. The decrease in density lipoprotein C in Incksland is similar, but it is more persistent, with a dose of a dose of treatment lasting six months. Common adverse effects include pain or swelling, fatigue, nausea and muscle pain in the injection area. Because it can also reduce the number of spots. Patients can choose according to their type of health insurance and their financial situation.
Blank
